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Heterogeneous ribonucleoprotein K (hnRNP K) is a member of the hnRNP family which has several different cellular roles including
transcription, mRNA shuttling, RNA editing and translation. Several reports implicate hnRNP K having a role in tumorigenesis, for
instance hnRNP K increases transcription of the oncogene c-myc and hnRNP K expression is regulated by the p53/MDM 2 pathway.
In this study comparing normal colon to colorectal cancer by proteomics, hnRNP K was identified as being overexpressed in this type
of cancer. Immunohistochemistry with a monoclonal antibody to hnRNP K (which we developed) on colorectal cancer tissue
microarray, confirmed that hnRNP K was overexpressed in colorectal cancer (Po0.001) and also showed that hnRNP K had an
aberrant subcellular localisation in cancer cells. In normal colon hnRNP K was exclusively nuclear whereas in colorectal cancer the
protein localised both in the cytoplasm and the nucleus. There were significant increases in both nuclear (P¼0.007) and cytoplasmic
(P¼0.001) expression of hnRNP K in Dukes C tumours compared with early stage tumours. In Dukes C patient’s good survival was
associated with increased hnRNP K nuclear expression (P¼0.0093). To elaborate on the recent observation that hnRNP K is
regulated by p53, the expression profiles of these two proteins were also analysed. There was no correlation between hnRNP K and
p53 expression, however, patients who presented tumours that were positive for hnRNP K and p53 had a poorer survival outcome
(P¼0.045).
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Initial reports describe the heterogeneous ribonucleoprotein
(hnRNP) family as a group of six proteins which bound RNA II
polymerase transcripts to form hnRNP particles. Subsequently
immuno-purification of the hnRNP complex identified additional
factors (Choi and Dreyfuss, 1984); there are in excess of 20 hnRNPs
and interestingly, certain family members are emerging as having
important roles in tumour development (Carpenter et al, 2006).
Heterogeneous ribonucleoprotein A2/B1 is the most extensively
studied member which is overexpressed in different tumour types
and preliminary studies indicate hnRNP A2/B1 may be a good
prognostic and diagnostic marker (Carpenter et al, 2006).
Heterogeneous ribonucleoprotein K is another hnRNP family
member that has been implicated in regulating tumorigenesis.
Heterogeneous ribonucleoprotein K is a 464 amino-acid protein
with 3K homology domains (KH) that mediate DNA and RNA
binding (Bomsztyk et al, 2004) and contains both nuclear
localisation and nuclear shuttling domains (Bomsztyk et al,
1997). Based on these domains it was presumed that the hnRNP
K protein is involved in multiple steps of gene expression
including transcription, RNA splicing and translation; such
presumptions were later confirmed. Heterogeneous ribonucleo-
protein K was shown to bind DNA in a CT element-dependent
manner (Takimoto et al, 1993). Of interest, such an element is
present in the oncogene c-myc, and overexpression of hnRNP K
increases the transcriptional activity of a c-myc gene reporter
(Takimoto et al, 1993). Also hnRNP K in combination with the
transcription factor SP1, binds and activates the c-src promoter
(Ritchie et al, 2003). Heterogeneous ribonucleoprotein K involve-
ment in splicing was demonstrated using the chicken b
tropomyosin gene, whose alternative splicing of exon 6A is
mediated by a downstream intronic enhancer. Heterogeneous
ribonucleoprotein K was identified as a protein present in the
intronic enhancer complex whose function is to activate splicing of
exon 6A (Expert-Bezancon et al, 2002). Heterogeneous ribonu-
cleoprotein K also mediates translation, in HeLa cells hnRNP K
silences translation of a luciferase reporter mRNA containing the
differentiation control element present in the 30UTR of the 15
lipoxygenase gene (Ostareck-Lederer et al, 1994). Furthermore,
hnRNP K stimulates translation of a c-myc-IRES reporter vector in
vivo (Evans et al, 2003).
Several cellular functions implicate hnRNP K as being involved
in the regulation of tumorigenesis. Recently, hnRNP K was
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sidentified as a member of the p53/MDM2 pathway (Moumen et al,
2005). Under normal cellular conditions, hnRNP K is degraded by
forming a complex with the E3 ligase MDM2. However, in cells
undergoing DNA damage MDM-2 dissociates from hnRNP K
through interaction with p53, resulting in increased hnRNP K
expression. Furthermore, hnRNP K is a coactivator for p53 target
genes and downregulation of hnRNP K in p53-positive cells, causes
defects in DNA damage-induced checkpoint arrests (Moumen
et al, 2005).
Heterogeneous ribonucleoprotein K increases the transcrip-
tional activity of the oncogenes c-myc and c-src and translation of
c-myc mRNA. A mutated version of the c-myc internal ribosomal
entry site which is found prevalently in patients with multiple
myeloma, is bound by hnRNP K more efficiently in vitro and
c-myc is translated to a greater extent by hnRNP K in vivo (Evans
et al, 2003). These observations suggest a possible mechanism
whereby hnRNP K contributes towards multiple myeloma, by
binding the mutant mRNA strand increasing translation of the
oncogene c-myc (Evans et al, 2003). The involvement of hnRNP K
in tumorigenesis is also based on the observations that growth
factors regulate hnRNP K expression (Mandal et al, 2001) and also
that hnRNP K is overexpressed in SV40-transformed cells
(Dejgaard et al, 1994). Null and weak alleles of bancal, a Drosophila
protein related to hnRNP K, impair adult appendage morphogen-
esis (Charroux et al, 1999; Gates and Thummel, 2000). Such a
phenotype occurs owing to decreased cell proliferation in the
imaginal discs showing that a homologue of hnRNP K is also
necessary for cell growth.
Heterogeneous ribonucleoprotein K has also been shown to be
involved in cell migration; a process necessary for cancer
metastasis. Modulation of cell adhesion is an important stage of
metastasis and interestingly a recently discovered structure termed
the spreading initiation centre was shown to exist in the early
stages of cell spreading (de Hoog et al, 2004). Using a lung
fibroblast cell line, spreading initiation centres were shown to
consist of several proteins, hnRNP K being one of them, and
interfering with hnRNP K, increased cell spreading (de Hoog et al,
2004). It was hypothesised by the authors that hnRNP K controls
cell spreading by a rate limiting process rather than inhibiting (de
Hoog et al, 2004). Nevertheless these observations provide
evidence of a connection between hnRNP K and initiation of cell
spreading, a process essential for tumour cell invasion and
metastasis.
Using a combination of two-dimensional (2D)-SDS-PAGE, mass
spectrometry and comparing normal colon to colorectal cancer
tissues, we identified hnRNP K as being overexpressed in
colorectal cancer. Subsequently, the expression profile of hnRNP
K with a monoclonal antibody to hnRNP K which we developed
was analysed in detail using a colorectal cancer tissue microarray
(TMA).
MATERIALS AND METHODS
Two-dimensional gel electrophoresis and peptide mass
mapping
Two-dimensional gel electrophoresis and matrix-assisted laser
desorption ionisation time of flight mass spectrometry (MALDI-
TOF) mass spectrometry on normal colon and colorectal tissues
were performed as previously described (Lawrie et al, 2004;
Dundas et al, 2005). Proteins were extracted from Dukes C
adenocarcinoma tissue samples and patient-matched morphologi-
cally normal colorectal mucosa (n¼10 pairs of tumour and
normal samples). Two-dimensional gel electrophoresis was
performed using 3–10pI immobilon strips. Following completion
of the electrophoresis, gels were stained with Coomassie Blue to
visualise proteins spots. The spots were excised from the gels and
peptide mass mapping MALDI-TOF MS was performed using a
PerSeptive Biosystems Voyager-DE STR mass spectrometer.
The masses of the tryptic fragments were determined using
MALDI-TOF MS, and entered into the MS-Fit database-searching
program (http://prospector.ucsf.edu/ucsfhtml14.0/msfit.htm). The
database was restricted to human proteins but no restriction was
placed on molecular weight or isoelectric point. To ensure that
proteins were accurately identified a significant difference in
statistical score between proteins ranked first and second in the
results had to be obtained.
Monoclonal antibody to heterogeneous
ribonucleoprotein K
A monoclonal antibody to hnRNP K was produced using a method
we have described previously (McFadyen et al, 1999). Briefly, a 10
amino-acid C-terminal peptide to hnRNP K (SVKQYSGKFF)
conjugated to ovalbumin was used to immunise mice subsequently
followed with a booster. The spleens of mice that demonstrated the
highest antibody titres as determined by ELISA using the peptide
immunogen were fused with myeloma cells. Antibody titres were
assessed again by ELISA after cloning of the hybridomas. The
specificity of the antibody was further confirmed by Western
blotting using immortalised human cells lines (HT29 and CALU1).
Tumour samples
This project had the permission of the Grampian Research Ethics
Committee. There were 268 patients in the study and the cases
were selected from the Aberdeen colorectal tumour bank. All the
patients had a diagnosis of primary colorectal cancer and had
undergone elective surgery for colorectal cancer, in Aberdeen,
between 1994 and 2003. The tumour samples had been submitted
to the Department of Pathology, University of Aberdeen for
diagnosis. The tumour excision specimens had been fixed in
formalin and representative blocks embedded in wax and sections
stained with haematoxylin and eosin. The clinico-pathological
characteristics (age, gender, site of primary tumour, degree of
primary tumour differentiation and Dukes stage) of the patients
included in this study are detailed in Table 1. Complete follow-up
Table 1 Clinicopathological features of the microarrayed colorectal
adenocarcinomas (number (%))
Gender
Male 135 (50.4%)
Female 133 (49.6%)
Age
Mean 68 years
Range 33–92 years
p70years 127 (47.4%)
470years 141 (52.6%)
Dukes stage
A 53 (19.8%)
B 104 (38.8%)
C 111 (41.4%)
Tumour site
Proximal colon 95 (35.4%)
Distal colon 97 (36.2%)
Rectum 76 (28.4%)
Tumour differentiation
Well 10 (3.7%)
Moderate 228 (85.1%)
Poor 30 (11.2%)
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swas available for all patients and ranged from 1 month to greater
than 117 months. There were 75 (28%) deaths in the patient group
with a median survival of greater than 117 months and a mean
survival of 80 months.
Tissue microarray
A colorectal cancer TMA was constructed as described previously
(Dundas et al, 2005). The TMA contained primary colorectal cancer
(Dukes A¼53, Dukes B¼104 and Dukes C¼111), 111 lymph node
metastasis and 53 normal morphologically colonic mucosal samples.
The lymph node metastasis were from the corresponding Dukes C
cases. The arrayed tumours reflected the distribution of the
anatomical locations and Dukes stage of colorectal cancer in this
population. A single normal colon sample was obtained from each
of the 53 colorectal cancer resection specimens and each sample was
acquired from at least 10cm distant from the tumour as described
previously (Dundas et al, 2005). One representative 1.6mm core of
tissue was taken from each donor block using a steel Menghini
needle and arrayed into the recipient wax block. One section from
each microarray was stained with haematoxylin and eosin to
confirm the histopathological diagnosis and the adequacy of
sampling. Sectioning and processing the microarray incurred a rate
of core loss of 5–15% consistent with other published studies
(Gulman and O’Grady, 2003).
Immunohistochemistry
Immunohistochemistry for hnRNP K was carried out using a Dako
autostainer (Dako Cytomation, Ely, UK). Sections (5mm) of the
TMA were dewaxed, rehydrated and an antigen retrieval step
performed. The antigen retrieval step consisted of microwaving the
sections in 0.01 M citrate buffer at pH 6.0 for 20min in an 800W
microwave oven operated at full power. The sections were then
allowed to cool to room temperature. Heterogeneous ribonucleo-
protein K (1 in 5) diluted in antibody diluent (Dako) was applied
for 60min at room temperature, washed with buffer (Dako)
followed by peroxidase blocking 5min (Dako) and a single 2min
buffer wash. Pre-diluted peroxidase-polymer labelled goat anti-
mouse/rabbit secondary antibody (Envisiont, Dako) was applied
for 30min at room temperature, followed by further washing with
buffer to remove unbound antibody. Sites of peroxidase activity
were then demonstrated with diaminobenzidine as the chromogen
applied for three successive 5-min periods. Finally sections were
washed in water, lightly counterstained with haematoxylin,
dehydrated and mounted. Omitting the primary antibody from
the immunohistochemical procedure and replacing it with anti-
body diluent acted as negative controls. For p53 staining a mouse
monoclonal antibody (Dako) was used after antigen retrieval at a
dilution of one in 40.
The sections were evaluated by light microscopic examination
and the intensity of immunostaining in each section assessed
independently by two observers (MM and GIM) using the scoring
system described. There were very few discrepancies (o5% of
cases) and these were resolved by simultaneous re-evaluation. Both
the intensity of immunostaining and proportion of cells staining
positively were assessed and the cellular compartment (nucleus v
cytoplasm) in which the immunoreactivity occurred also noted.
The intensity of immunostaining in each core was graded as
negative¼zero, weak¼1, moderate¼2 or strong¼3 (Dundas
et al, 2005). The proportion of cells staining positively were
assessed as no cells¼0, 1–25% of cells¼1, 26–50%¼2, 51–
75%¼3 and 76–100%¼4. The numbers representing intensity
and percentage cells stained were added together to give either a
nuclear or cytoplasmic score and will now be referred to as score.
The scores were then banded as follows 0¼negative, 2, 3, 4¼low
and 5, 6, 7¼high for further analysis. Tumours stained for p53
were scored as being either positive or negative.
Statistical analysis
Statistical analyses including w
2 test, t-test, and Kaplan–Meier
survival analysis were performed using SPSS v11.5 for Windows
XPt (SPSS UK, Ltd, Woking, UK). The log-rank test was used to
determine survival differences between individual groups. We
regarded Po0.05 as significant.
RESULTS
Identification of heterogeneous ribonucleoprotein K as
being overexpressed in colorectal cancer
To identify potential biomarkers of colorectal cancer, whole-cell
lysates of normal colon and primary Duke C colorectal tumours
were separated by 2D SDS-PAGE, which allowed the two protein
profiles to be compared (Figure 1). Spots which were observed
uniquely in the tumour samples were subsequently excised and
identified by MALDI-TOF. One consistently overexpressed protein
spot highlighted in tumour samples was identified using mass
spectrometry, MS (Figure 1). The predicted mass of the protein
and peptide mass analysis identified it as hnRNP K, the MOWSE
score (20400) was significantly higher for hnRNP K compared
with the next protein.
The specificity of the monoclonal antibody to hnRNP K was
determined by ELISA using the immunogenic peptide (data not
shown) and also by Western blotting (Figure 2) using two cells
lines isolated from lung (CALU1) and colon (HT29) carcinomas. A
single band migrating at the expected molecular weight was
observed. The validated hnRNP K monoclonal antibody was
subsequently used to immunostain the colorectal TMA.
Cellular localisation and expression profile of
heterogeneous ribonucleoprotein K in colorectal cancer
In normal colon (Figure 3A) hnRNP K localisation was exclusively
nuclear with no cytoplasmic expression. In primary colorectal
tumour tissues however, hnRNP K localised both in the nucleus
and the cytoplasm (Figure 3B and C). The same hnRNP K staining
profile observed in the primary colorectal tissues was also
observed in the lymph node metastasis.
In agreement with the 2D-SDS-PAGE and MALDI-TOF analysis,
total mean score of hnRNP K was significantly (Po0.001) higher in
primary tumour compared to normal colon (Figure 4A).
Mean score was subsequently analysed based on subcellular
localisation. A significant decrease (comparing normal colon to
primary tumour and primary tumour to lymph node metastasis
Po0.001 and P¼0.006, respectively) in mean nuclear stain
100 kDa
15 kDa
pI 3.0 pI 10.0 pI 3.0 pI 10.0
AB
Figure 1 Coomassie-stained 2D SDS-PAGE gels showing whole-cell
lysates of normal colon (A) and colorectal tumour samples (B). Circle
highlights a protein spot present in the tumour samples but not in the
normal tissue, which was identified as hnRNP K by MALDI-TOF MS
analysis. Molecular weight (Mw) and pI values are shown.
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(Figure 4B). For cytoplasmic hnRNP K mean score (Figure 4C) a
significant increase was observed only when normal colon was
compared with primary tumours (Po0.001).
Relationship of heterogeneous ribonucleoprotein K
expression, clinico-pathological parameters and survival
There were significant increases in both nuclear (P¼0.007) and
cytoplasmic (P¼0.001) hnRNP K in Dukes C tumours (Figure 5).
There was no relationship between either nuclear score or
cytoplasmic score and tumour site, tumour differentiation and
gender or age.
There was no correlation between overall survival and hnRNP K
nuclear or cytoplasmic expression. However, in patients with
Dukes C tumours there was poorer survival in those patients
whose tumours had a low or negative nuclear hnRNP K score
compared with those patients whose tumour had high nuclear
hnRNP K score (log rank¼6.77, P¼0.0093, Figure 6). In the poor
survival group (negative or low hnRNP K nuclear expression,
n¼15) the mean survival time was 23.4 months whereas in the
good survival cohort (high hnRNP K nuclear expression, n¼87),
the mean survival time was 64.1 months.
Heterogeneous ribonucleoprotein K and p53 expression in
colorectal cancer tissues
Heterogeneous ribonucleoprotein K and p53 expression were
compared based on a scoring system of 1 and 0 for expression and
absence of expression, respectively. p53 was localised exclusively
in the nucleus (Table 2). The hypothesis that p53 regulates hnRNP
K expression was tested first (Table 2a). Tumours were divided in
to four groups p53þ/hnRNP Kþ, p53þ/hnRNP K-, p53 /
hnRNP Kþ and p53 /hnRNP K. There was no correlation
between p53 and hnRNP K expression irrespective of hnRNP K
cellular localisation. For instance, the percentage tumours which
were hnRNP K nuclear or cytoplasmicþwere the same irrespective
of p53 expression (91.2% p53þvs 92.4% p53 – for hnRNP K
nuclear and 93.6% p53þvs 92.4% p53 – for cytoplasmic hnRNP
K). Heterogeneous ribonucleoprotein K also did not appear to
regulate p53 expression (Table 2b), the percentage of p53þ
tumours were similar irrespective of hnRNP K nuclear expression
(60.9% hnRNP K nuclearþvs 64.7% hnRNP K nuclear  ).
Analysis (Figure 7) did show that there was a significant (log
rank¼4.001, P¼0.045) survival trend, patients who presented
p53þ/hnRNP Kþ colorectal tumours (n¼119) had a poorer
survival outcome compared to patients with tumours of varied
p53/hnRNP K expression, n¼85 (p53þ/hnRNP K-, p53 /hnRNP
Kþ and p53 /hnRNP K ). The mean survival time for the good
survival cohort was 77.5 months vs 68 months for the poor survival
cohort (p53þ/hnRNP Kþ). There were no significant survival
differences within individual Dukes stages. Additionally, there
were no differences between the two groups regarding patient age
and gender, tumour stage, tumour site or tumour differentiation.
DISCUSSION
Colorectal cancer is one of the commonest cancers in the Western
world whose incidence is continuing to rise. A significant
proportion of patients present with locally advanced disease and
current therapy is based on a 5-fluorouracil regimen. Even with
treatment the 5-year survival rate is still relatively poor at
approximately 40%. Therefore, owing to the poor survival outcome
hnRNP K
CAL U1
HT 29
Figure 2 Immunoblot showing specificity of the hnRNP K monoclonal
antibody. Whole-cell lysates of CAL U1 and HT 29 reveal the monoclonal
antibody recognises a single band, migrating at the expected molecular
weight for hnRNP K by Western blotting.
Figure 3 Immunoreactivity for hnRNP K in normal colon and colorectal
cancer. (A) In normal colon, hnRNP K immunoreactivity is exclusively
present in the nuclei of crypt epithelial cells. (B) Strong nuclear and
cytoplasmic staining in primary colorectal cancer. (C) Strong nuclear and
weak cytoplasmic staining in primary colorectal neoplasm.
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sit is important to identify biomarkers of colorectal cancer to
facilitate early diagnosis. Importantly, biomarkers that are over-
expressed or even more beneficial, present solely in the cancer
tissues potentially act as specific targets for anti cancer therapeu-
tics. Using a combination of 2D-SDS-PAGE, mass spectrometry
and comparing normal colon to colorectal cancer tissues, we
identified hnRNP K protein as being overexpressed in colorectal
cancer. Further analysis using immunohistochemistry and a tissue
database showed that hnRNP K was overexpressed in colorectal
cancer. In support of these findings hnRNP K has been found to be
upregulated in several different cancer types inclusive of lung
(Pino et al, 2003) and liver cancer (Ostrowski and Bomsztyk,
2003). Interestingly in the cancer tissues hnRNP K localisation was
aberrant; in normal colon hnRNP K was present exclusively in the
nucleus whereas in tumour tissues the protein was observed both
in the cytoplasm and the nucleus and in Dukes C cancers both
nuclear and cytoplasmic hnRNP K was significantly increased
compared with early stage tumours. Such changes in cellular
localisation of hnRNP K has also been observed in smooth muscle
cells (SMC). In response to serum stimulation of SMC in vitro,
hnRNP K protein levels increased and the protein translocated
from the nucleus to the cytoplasm (Laury-Kleintop et al, 2005).
Differences in hnRNP K localisation appear to be modulated by
post-translational modificiation, phosphorylation of hnRNP K by
mitogen-activated protein kinase (MAPK) results in cytoplasmic
localisation of hnRNP K. Serum stimulation is necessary for MAPK
phosphorylation of hnRNP K which is indicative of cellular growth
(Habelhah et al, 2001). Additionally, there is evidence to show that
hnRNP K upregulation is a cause rather than an effect of
proliferation; overexpression of hnRNP K in breast cancer cells
significantly increases cell proliferation and growth in an
anchorage-independent manner (Mandal et al, 2001).
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Figure 4 Mean score of hnRNP K in normal colon, primary tumour and
metastatic tissues. (A) Total mean scores showed that there was a
significant increase in hnRNP K expression when comparing normal colon
to primary colorectal cancer (Po0.001). Subsequently mean scores were
evaluated based on cellular localisation, nuclear (B) and cytoplasm (C). (B)
As tumour stage progressed hnRNP K nuclear expression significantly
decreased (normal to tumour Po0.001 and tumour to metastasis
P¼0.006). (C) No hnRNP K expression was observed in the cytoplasm
of normal tissue but there was a significant increase in cytoplasmic
immunoreactivity (Po0.001) in primary tumours. No difference was
observed in mean hnRNP K cytoplasmic score for the tumour to metastasis
transition.
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Figure 5 The mean nuclear and cytoplasmic score in the different stages
of colorectal cancer. There are significant increases in both nuclear (A) and
cytoplasmic (B) hnRNP K in Dukes C tumours (P¼0.007 and 0.001,
respectively).
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Figure 6 Comparison of survival in patients whose tumours with a high
nuclear hnRNP K expression and those tumours with a low or moderate
nuclear hnRNP K expression. There is poorer survival in those patients
whose tumours with a low or moderate hnRNP K nuclear expression
compared with those patients whose tumours have a high nuclear
expression (log rank¼6.77, P¼0.0093).
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colorectal cancer cells? Heterogeneous ribonucleoprotein K has
several cellular roles including transcription, mRNA splicing and
translation. It is therefore tempting and not unreasonable to
suggest that hnRNP K has different roles in normal colon and
colorectal cancer. In normal colon cells, hnRNP K may be involved
in regulating DNA process such as transcription whereas in
tumour tissues hnRNP K may be involved in RNA-related
functions such as shuttling of mRNAs important for cellular
growth, splicing and translation. In support of this hypothesis it
has already been shown that hnRNP K enhances the translation of
the c-myc mRNA (Evans et al, 2003) and hnRNP K has also been
shown to have a cytoplasmic-based role relevant to cell metastasis
(Moumen et al, 2005).
Survival analysis showed that in Dukes C patients the stronger
the nuclear hnRNP K expression the better the survival outcome.
In squamous cell lung cancer high expression hnRNP B1 has also
been shown to be associated with improved survival (Wu et al,
2003). Such observations indicate that certain hnRNP family
members may be prognostic markers for colorectal cancer.
Moumen et al (2005) have shown that in response to DNA
damage, p53 inhibits hnRNP K ubiquitin-dependent proteasomal
degradation. We showed hnRNP K is overexpressed in colorectal
cancer; it was therefore decided to determine whether this increase
in expression was related to p53. Surprisingly, there was no
correlation between p53 and hnRNP K expression. One plausible
explanation is p53 may only stabilise hnRNP K expression as a
consequence of DNA damage, where as during other cellular
functions such as division hnRNP K expression could possibly be
regulated by alternative mechanisms. In support of this reason
Moumen and co-workers showed that only DNA-damaging agents
such as ultra violet light or ionising radiation induced hnRNP K
stabilisation through p53, whereas other stress stimuli such as
hypotonic or hypertonic conditions or heat-shock failed to
produce such a response. Further experiments will therefore be
needed to determine how hnRNP K expression is increased and/or
stabilised in colorectal cancers. The growth factors epidermal
growth factor and heregulin-b1 have already been reported to
increase expression hnRNP K mRNA and protein (Mandal et al,
2001) presenting two possible pathways for further analysis.
Interestingly, correlating survival with p53 and hnRNP K
expression (nuclear or cytoplasmic) did show a significant trend.
Patients who presented tumours that were positive for both p53
and hnRNP K expression had a poorer survival outcome compared
with other combinations (p53þ/hnRNP K-, p53 /hnRNP Kþ
and p53 /hnRNP K ). It therefore appears p53 and hnRNP K-
positive tumours are more aggressive. Interestingly, p53 and
hnRNP K cooperate to augment transcription of target genes
(Moumen et al, 2005), providing one possible reason why tumours
simultaneously expressing these proteins are more aggressive.
In summary, hnRNP K was shown to be overexpressed in
colorectal cancer cells and its subcellular localisation was aberrant;
in normal colon cells hnRNP K was exclusively nuclear whereas in
tumour cells this hnRNP family member was present both in the
cytoplasm and the nucleus. Additionally, Dukes C patients who
presented tumours with strong hnRNP K nuclear expression had a
better survival outcome.
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Table 2 Comparing expression of hnRNP K and p53 in colorectal cancer
tissues
(a)
p53 hnRNP K nuclear Percent of tumours
+ + 91.2% (114/125)
+   8.8% (11/125)
  + 92.4% (73/79)
   7.6% (6/79)
p53 hnRNP K cytoplasmic Percent of tumours
+ + 93.6% (117/125)
+   6.4% (8/125)
  + 92.4 (73/79)
   7.6 (6/79)
(b)
hnRNP K nuclear p53 Percent of tumours
+ + 60.9% (114/187)
+   39.1 (73/187)
  + 64.7% (11/17)
   35% (6/17)
hnRNP K cytoplasmic p53 Percent of tumours
+ + 61.2% (117/191)
+   38.2% (74/191)
  + 61.5 (8/13)
   38.4 (5/13)
hnRNP K¼heterogeneous ribonucleoprotein K. The expression of p53 was
compared to nuclear or cytoplasmic hnRNP K staining. Absence or presence of
the protein is represented by a   or +, respectively.
hnRNP K/p53
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Figure 7 Survival analysis patients who presented tumours that were
hnRNP Kþ/p53þhad a poor survival outcome compared to patients with
tumours that were either negative for both proteins or, p53þ/hnRNP K 
or p53 /hnRNP Kþ(log rank¼4.001, P¼0.045).
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